Medicare pays for some weight loss treatments related to obesity, including counseling and certain surgeries. However, it does not usually cover weight loss programs for general health.

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

If Medicare were to cover anti-obesity medications (AOMs), federal spending would increase about $35 million between 2026 and 2034, finds a new Congressional Budget Office report.

So far, benefits associated with consistent GLP-1 use in curbing medical spending lack sufficient data-backed evidence. It’s ...

Medicare does not cover prescription weight loss drugs like Meridia unless prescribed for another reason. Learn about coverage with Medicare.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Medicare coverage of the drugs would up federal spending by $35 billion from 2026 to 2034. Meanwhile, CNBC tests Abbott’s continuous glucose monitor Lingo.

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...

Natalie Muth, MD, MPH, RDN, is an adjunct associate professor at UCLA Fielding School of Public Health; co-founder of Namio Health, a virtual intensive behavioral intervention for the treatment of ...